Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.45 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7603869 | 0.79 | SLC6A2 (0.61) | USP2SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL13434175 | 0.78 | HSD17B10 (0.54) | USP2HPGDHSD17B10SLC6A2SLC6A4 | |
| SCHEMBL31470002 | 0.77 | USP2 (0.65) | USP2HPGDHSD17B10SLC6A2SLC6A4 | |
| SCHEMBL27814646 | 0.75 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL24392681 | 0.74 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL12075444 | 0.73 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4151481 | 0.71 | CNR2 (0.45) | USP2HPGDHSD17B10SLC6A2SLC6A4 | |
| SCHEMBL295502 | 0.71 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL5428676 | 0.71 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3GBA1 | |
| SCHEMBL3192672 | 0.70 | CNR2 (0.65) | USP2HPGDHSD17B10RORCCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | HALE JEFFREY J (US) | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | CCR5, CCR1, CXCR1 | USP2 4703/4885HPGD 905/4885HSD17B10 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.